Skip to main content
Top
Published in: Journal of Neurology 12/2012

Open Access 01-12-2012 | Review

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value

Authors: E. Zoons, M. G. W. Dijkgraaf, J. M. Dijk, I. N. van Schaik, M. A. Tijssen

Published in: Journal of Neurology | Issue 12/2012

Login to get access

Abstract

Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20–50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47–50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects.
Appendix
Available only for authorised users
Literature
2.
go back to reference Ben-Shlomo Y, Camfield L, Warner T (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608–614PubMedCrossRef Ben-Shlomo Y, Camfield L, Warner T (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608–614PubMedCrossRef
3.
go back to reference Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066–1072PubMedCrossRef Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066–1072PubMedCrossRef
4.
go back to reference Brefel-Courbon C, Simonetta-Moreau M, More C, Rascol O, Clanet M, Montastruc JL, Lapeyre-Mestre M (2000) A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 23:203–207PubMedCrossRef Brefel-Courbon C, Simonetta-Moreau M, More C, Rascol O, Clanet M, Montastruc JL, Lapeyre-Mestre M (2000) A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 23:203–207PubMedCrossRef
5.
go back to reference Burbaud P, Ducerf C, Cugy E, Dubos JL, Muller F, Guehl D, Dehail P, Cugy D, Moore N, Lagueny A, Joseph PA (2011) Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 258:1670–1675PubMedCrossRef Burbaud P, Ducerf C, Cugy E, Dubos JL, Muller F, Guehl D, Dehail P, Cugy D, Moore N, Lagueny A, Joseph PA (2011) Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 258:1670–1675PubMedCrossRef
6.
go back to reference Camfield L, Ben-Shlomo Y, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838–841PubMedCrossRef Camfield L, Ben-Shlomo Y, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838–841PubMedCrossRef
7.
go back to reference Chadda S, Tilden D, Jones D, Hawthorne M, Wolf T, Sykes D (2009) Cost-effectiveness of xeominspi in the management of cervical dystonia and blepharospasm. EJHP Practice 15:39–46 Chadda S, Tilden D, Jones D, Hawthorne M, Wolf T, Sykes D (2009) Cost-effectiveness of xeominspi in the management of cervical dystonia and blepharospasm. EJHP Practice 15:39–46
8.
go back to reference Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325–1337PubMedCrossRef Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325–1337PubMedCrossRef
9.
go back to reference Crowner BE, Torres-Russotto D, Carter AR, Racette BA (2010) Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 33:243–247PubMedCrossRef Crowner BE, Torres-Russotto D, Carter AR, Racette BA (2010) Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 33:243–247PubMedCrossRef
10.
go back to reference Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH (1997) Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 12:695–706PubMedCrossRef Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH (1997) Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 12:695–706PubMedCrossRef
11.
go back to reference ESDE (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787–792CrossRef ESDE (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787–792CrossRef
12.
go back to reference Gudex CM, Hawthorne MR, Butler AG, Duffey P (1998) Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 13:941–946PubMedCrossRef Gudex CM, Hawthorne MR, Butler AG, Duffey P (1998) Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 13:941–946PubMedCrossRef
13.
go back to reference Gudex CM, Hawthorne MR, Butler AG, Duffey PO (1997) Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis. Pharmacoeconomics 12:675–684 Gudex CM, Hawthorne MR, Butler AG, Duffey PO (1997) Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis. Pharmacoeconomics 12:675–684
14.
go back to reference Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622–629PubMed Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622–629PubMed
15.
go back to reference Hall TA, McGwin G Jr, Searcey K, Xie A, Hupp SL, Owsley C, Kline LB (2006) Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 124:116–119PubMedCrossRef Hall TA, McGwin G Jr, Searcey K, Xie A, Hupp SL, Owsley C, Kline LB (2006) Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 124:116–119PubMedCrossRef
16.
go back to reference Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J (2001) Health-related quality of life is improved by botulinum neurotoxin type A in long-term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193–199PubMedCrossRef Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J (2001) Health-related quality of life is improved by botulinum neurotoxin type A in long-term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193–199PubMedCrossRef
18.
go back to reference Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD (2007) Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 78:264–270PubMedCrossRef Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD (2007) Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 78:264–270PubMedCrossRef
19.
go back to reference Le KD, Nilsen B, Dietrichs E (2003) Prevalence of primary focal and segmental dystonia in Oslo. Neurology 61:1294–1296PubMedCrossRef Le KD, Nilsen B, Dietrichs E (2003) Prevalence of primary focal and segmental dystonia in Oslo. Neurology 61:1294–1296PubMedCrossRef
20.
go back to reference Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25:534–541PubMedCrossRef Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25:534–541PubMedCrossRef
21.
go back to reference Martikainen KK, Luukkaala TH, Marttila RJ (2010) Working capacity and cervical dystonia. Parkinsonism Relat Disord 16:215–217PubMedCrossRef Martikainen KK, Luukkaala TH, Marttila RJ (2010) Working capacity and cervical dystonia. Parkinsonism Relat Disord 16:215–217PubMedCrossRef
22.
go back to reference Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA (2009) Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 24:1384–1387PubMedCrossRef Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA (2009) Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 24:1384–1387PubMedCrossRef
23.
go back to reference Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842–846PubMedCrossRef Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842–846PubMedCrossRef
24.
go back to reference Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164PubMedCrossRef Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164PubMedCrossRef
25.
go back to reference Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J (2010) Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report–Part VI. Value Health 13:28–33PubMedCrossRef Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J (2010) Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report–Part VI. Value Health 13:28–33PubMedCrossRef
26.
go back to reference Skogseid IM, Malt UF, Roislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129–1137PubMedCrossRef Skogseid IM, Malt UF, Roislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129–1137PubMedCrossRef
27.
go back to reference Skogseid IM, Roislien J, Claussen B, Kerty E (2005) Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604–1609PubMedCrossRef Skogseid IM, Roislien J, Claussen B, Kerty E (2005) Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604–1609PubMedCrossRef
28.
go back to reference Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22:95–100PubMed Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22:95–100PubMed
29.
go back to reference Smith AG (2004) Pearls and pitfalls in the therapeutic use of botulinum toxin. Semin Neurol 24:165–174PubMedCrossRef Smith AG (2004) Pearls and pitfalls in the therapeutic use of botulinum toxin. Semin Neurol 24:165–174PubMedCrossRef
30.
go back to reference Snaith A, Wade D (2011) Dystonia. Clin Evid (Online) Snaith A, Wade D (2011) Dystonia. Clin Evid (Online)
31.
go back to reference Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME (2011) Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 120:465–473PubMed Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME (2011) Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 120:465–473PubMed
33.
go back to reference Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K (1991) Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 101:630–634PubMed Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K (1991) Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 101:630–634PubMed
34.
go back to reference Truong D, Comella C, Fernandez HH, Ondo WG (2008) Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407–414PubMedCrossRef Truong D, Comella C, Fernandez HH, Ondo WG (2008) Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407–414PubMedCrossRef
35.
go back to reference Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49–52PubMedCrossRef Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49–52PubMedCrossRef
36.
go back to reference von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15:473–490CrossRef von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15:473–490CrossRef
37.
go back to reference Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233–239PubMedCrossRef Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233–239PubMedCrossRef
38.
go back to reference Weinberger M, Samsa GP, Hanlon JT, Schmader K, Doyle ME, Cowper PA, Uttech KM, Cohen HJ, Feussner JR (1991) An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc 39:691–694PubMed Weinberger M, Samsa GP, Hanlon JT, Schmader K, Doyle ME, Cowper PA, Uttech KM, Cohen HJ, Feussner JR (1991) An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc 39:691–694PubMed
39.
go back to reference Welter ML, Grabli D, Vidailhet M (2010) Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol 23:420–425PubMed Welter ML, Grabli D, Vidailhet M (2010) Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol 23:420–425PubMed
40.
go back to reference Whitaker J, Butler A, Semlyen JK, Barnes MP (2001) Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Arch Phys Med Rehabil 82:480–484PubMedCrossRef Whitaker J, Butler A, Semlyen JK, Barnes MP (2001) Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Arch Phys Med Rehabil 82:480–484PubMedCrossRef
41.
Metadata
Title
Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
Authors
E. Zoons
M. G. W. Dijkgraaf
J. M. Dijk
I. N. van Schaik
M. A. Tijssen
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 12/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6510-x

Other articles of this Issue 12/2012

Journal of Neurology 12/2012 Go to the issue